Clinical trial
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NCT03166098 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
- Lead sponsor
- NYU Langone Health
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 5, 2016
- Completion date
- March 1, 2022
- Enrollment
- 139 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.